ArticleMedComm2025
Oral Anticoagulant Therapy of Patients With Atrial Fibrillation in Cardiology, Internal Medicine, and Surgery: Temporal Trend.
Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disparities in anticoagulation therapy for older adults with non-valvular atrial fibrillation: a comparative study of urban and suburban communities.BMC geriatrics · 2026Article
- Oral Anticoagulant Therapy of Patients With Atrial Fibrillation in Cardiology, Internal Medicine, and Surgery: Temporal Trend.MedComm · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess the status of oral anticoagulant (OAC) therapy among Chinese patients with atrial fibrillation (AF) across various hospital departments, influenced by recent changes in medical insurance policies. It retrospectively analyzed data from 70,187 AF patients treated between January 2018 and December 2023 across 20 hospitals. The average patient age was 72.3 years, with 54.4% male. The study found a significant increase in OAC use over time, particularly in cardiology, where the usage rose from 29.8% pre-2018 to 68.8% in 2021-2023. However, OAC usage in non-cardiology departments remained below 50% during the same period. Tertiary hospitals had higher OAC prescription rates compared to non-tertiary hospitals. Despite 77.4% of the cohort being at high risk for stroke, their OAC usage rates were not higher than the non-high-risk group. Factors such as advanced age, history of bleeding, hemoglobin levels, and concurrent antiplatelet therapy hindered OAC use, while upstream treatments facilitated its acceptance. The study concludes that while progress has been made in OAC prescription in China, significant gaps remain, especially in internal medicine and surgery departments, necessitating targeted interventions and better interdisciplinary collaboration for improved patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.